RT Journal Article
SR Electronic
T1 A deep-learning-based two-compartment predictive model (PKRNN-2CM) for vancomycin therapeutic drug monitoring
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.30.24302025
DO 10.1101/2024.01.30.24302025
A1 Mao, Bingyu
A1 Xie, Ziqian
A1 Nigo, Masayuki
A1 Rasmy, Laila
A1 Zhi, Degui
YR 2024
UL http://medrxiv.org/content/early/2024/01/31/2024.01.30.24302025.abstract
AB Objective Vancomycin is a widely used antibiotic that requires therapeutic drug monitoring (TDM) for optimized individual dosage. The deep learning-based model PKRNN-1CM has shown the advantage of leveraging time series electronic health record (EHR) data for individualized estimation of vancomycin pharmacokinetic (PK) parameters. While one-compartment (1CM) PK models are commonly used because of their simplicity and previous trough-based clinical practices for dose adjustment, the pre-deep learning literature suggests the superiority of two-compartment models (2CM). Motivated by this, we introduce a novel deep-learning-based approach, PKRNN-2CM, for vancomycin TDM.Methods PKRNN-2CM combines RNN-driven PK parameter estimation with a 2CM PK model to predict vancomycin concentration trajectories. Training on both simulated data and real-world EHR data allows for a comprehensive evaluation of its performance.Results Experiments based on simulated data highlight PKRNN-2CM’s superiority over the simpler 1CM model PKRNN-1CM (PKRNN-2CM RMSE=1.30, PKRNN-1CM RMSE=2.50). Application to real data showcases significant improvement over PKRNN-1CM (PKRNN-2CM RMSE=5.62, PKRNN-1CM RMSE=5.84, two-sample unpaired t-test p-value=0.01), with potential further gains expected with non-trough level measurements.Conclusion PKRNN-2CM is an important improvement in vancomycin TDM, demonstrating enhanced accuracy and performance compared to the PKRNN-1CM model. This deep learning model holds potential for future individualized vancomycin TDM optimization and broader application in diverse clinical scenarios.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Committee for the Protection of Human Subjects in the University of Texas Health Science Center at Houston (UTHSC-H IRB) under protocol HSC-MS-19-1011.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study contains protected health information (PHI) that is not allowed to be shared. https://github.com/ZhiGroup/PK-RNN/tree/PKRNN-2CM 1CMOne-compartment2CMTwo-compartmentAUCArea Under the CurveEHRElectronic Health RecordGRUGated Recurrent UnitMHHSMemorial Hermann Health SystemODEOrdinary Differential EquationPKPharmacokineticRMSERoot Mean Square ErrorRNNRecurrent Neural NetworkTDMTherapeutic Drug Monitoring